Announcements Trials
Browse Landscape

Phase

Phase 1 31Phase 2 30Phase 1/2 17Phase NA 4Phase 3 4Phase 2/3 2Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 10fludarabine 5Etoposide 5venetoclax 3Stem Cell Transplantation 3Sirolimus 3Exercise 3Cytarabine 3pembrolizumab 2Vincristine 2Transplantation 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Magnetic Resonance Spectroscopy 2Influenza Vaccines 2Immunotherapy, Adoptive 2Ifosfamide 2Idarubicin 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Doxorubicin 2Dexamethasone 2Counseling 2Cord Blood Stem Cell Transplantation 2Biopsy 2Azacitidine 2siltuximab 1ruxolitinib 1pirtobrutinib 1nilotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Injections × Other hematologic neoplasm × Clear all
NCT04628338 2025-04-29

IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation

University of Pittsburgh

Phase EARLY_PHASE1 Completed
8 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Leukemia, Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡